NCT05475431Completed
Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity
The Most Appropriate Prescription of the First-line, the Second-line, and the Third Treatment for H. Pylori Eradication Among Patients Who Are Comorbid Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, or Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 7 Nov 2024
Brief summary (registry, in English)
Most of the studies of H. pylori eradication were conducted in academic institutes and designed to enrolled patients who did not have comorbidities. However, patients in the real world may comorbid with diabetes, chronic obstructive pulmonary disease, cirrhosis, chronic kidney diseases, or others. We hypothesize that the eradication rate of H. pylori in patients with comorbidity is poor because they may be infected with antibiotics-resistant H. pylori strains or have poor medication adherence. Here, we design a study, which focus on the H. pylori eradication rates by the various regimens in the real world, especially for those with high Charlson scores. It is presumed that our data will be helpful with regard to treating such patients with H. pylori eradication in the clinical scenario.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1053 (actual)
- First submitted
- 24 Jul 2022
- Start date
- 6 May 2020
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- National Cheng-Kung University Hospital
- Diseases
- Chronic kidney disease, COPD
- NCT number
- NCT05475431
What you commit to
- Study type: Observational
- Participants enrolled: 1053
- From 6 May 2020 to the primary completion date, 31 Dec 2023
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients are excluded if they ever received H. pylori eradication before.
Who the study is looking for
- Patients who are \>= 20 years and received the therapy for H. pylori eradication from January 1, 2012 to December 31, 2019 are reviewed retrospectively. The regimens include 10- or 14-day sequential therapy, 7-, 10-, or 14-day triple therapy, 10- or 14-day hybrid therapy, 7- or 14-day concomitant therapy, 10- or 14-day bismuth-based quadruple therapy.
Age in the registry: 20 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Helicobacter pylori study group, National Cheng Kung University Hospital Coordinator of this site? Confirm its status | Tainan | Taiwan | Unknown status |
| National Cheng Kung University Hospital Coordinator of this site? Confirm its status | Tainan | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.